Taken together, these data demonstrate that inhibition of NRF2 signaling might represent a valid therapeutic option in those malignant tumors wherein genetic, epigenetic, or upstream oncogenic alterations lead to persistent NRF2 overactivation. Here, NFE2L2 is linked to cancer.